Latest news with #XerisBiopharmaHoldings'
Yahoo
26-04-2025
- Business
- Yahoo
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Xeris Biopharma Holdings, Inc.'s () future prospects. Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. On 31 December 2024, the US$659m market-cap company posted a loss of US$55m for its most recent financial year. As path to profitability is the topic on Xeris Biopharma Holdings' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. According to the 6 industry analysts covering Xeris Biopharma Holdings, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$17m in 2026. So, the company is predicted to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 60%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected. We're not going to go through company-specific developments for Xeris Biopharma Holdings given that this is a high-level summary, however, take into account that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. View our latest analysis for Xeris Biopharma Holdings One thing we would like to bring into light with Xeris Biopharma Holdings is it currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning. This article is not intended to be a comprehensive analysis on Xeris Biopharma Holdings, so if you are interested in understanding the company at a deeper level, take a look at Xeris Biopharma Holdings' company page on Simply Wall St. We've also put together a list of relevant factors you should look at: Valuation: What is Xeris Biopharma Holdings worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Xeris Biopharma Holdings is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Xeris Biopharma Holdings's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
19-02-2025
- Business
- Yahoo
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions
Significant control over Xeris Biopharma Holdings by retail investors implies that the general public has more power to influence management and governance-related decisions 41% of the business is held by the top 25 shareholders Institutional ownership in Xeris Biopharma Holdings is 45% A look at the shareholders of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) can tell us which group is most powerful. The group holding the most number of shares in the company, around 50% to be precise, is retail investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And institutions on the other hand have a 45% ownership in the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Let's take a closer look to see what the different types of shareholders can tell us about Xeris Biopharma Holdings. Check out our latest analysis for Xeris Biopharma Holdings Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Xeris Biopharma Holdings does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Xeris Biopharma Holdings' earnings history below. Of course, the future is what really matters. We note that hedge funds don't have a meaningful investment in Xeris Biopharma Holdings. Our data shows that BlackRock, Inc. is the largest shareholder with 7.3% of shares outstanding. With 5.3% and 3.4% of the shares outstanding respectively, The Vanguard Group, Inc. and Caxton Associates (USA) LLC are the second and third largest shareholders. Furthermore, CEO John Shannon is the owner of 0.6% of the company's shares. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. We can report that insiders do own shares in Xeris Biopharma Holdings, Inc.. It has a market capitalization of just US$535m, and insiders have US$26m worth of shares, in their own names. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Xeris Biopharma Holdings. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Xeris Biopharma Holdings . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
